Molecular diagnostics company GeneCentric collects $2.5 million for cancer tests
Using the genetic properties of tumors to classify them more specifically and determine whether they may respond to anti-angiogenic drugs has netted a two-year-old diagnostics firm a $2.5 million round. GeneCentric Diagnostics Inc. is now a commercial-stage company, said former LabCorp exec Dr. Myla Lai-Goldman, who is now CEO of GeneCentric and a venture partner […]